Literature DB >> 18563338

Immune killing activity of lymphocytes on Hela cells expressing interleukin-12 in vitro.

Huiyan Wang1, Suhua Chen.   

Abstract

The killing effects of lymphocytes on Hela cells expressing interleukin-12 (IL-12) in vitro were explored. By using gene transfection technique, full length IL-12 gene was transfected into Hela cells. The expression of IL-12 in Hela cells was detected quantitatively by ELISA; Changes in killing effects of lymphocytes on Hela cells expressing IL-12 were observed by MTT. It was found that Hela cells could express IL-12 between 24 h and 72 h after transfection. Killing activity of lymphocytes on Hela cells expressing IL-12 was significantly enhanced. It was concluded by cell transfection technique, Hela cells could express IL-12 and were more easily killed by lymphocytes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18563338     DOI： 10.1007/s11596-008-0326-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN： 1672-0733


  9 in total

1.  Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy.

Authors:  R Sanches; M Kuiper; F Penault-Llorca; B Aunoble; C D'Incan; Y J Bignon
Journal:  Cancer Gene Ther       Date:  2000-05       Impact factor: 5.987

Review 2.  Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review).

Authors:  J Golab; R Zagozdzon
Journal:  Int J Mol Med       Date:  1999-05       Impact factor: 4.101

Review 3.  Role of IL12 as an anti-tumour agent: current status and future directions.

Authors:  M J Brunda
Journal:  Res Immunol       Date:  1995 Sep-Oct

Review 4.  Interleukin-12 in anti-tumor immunity and immunotherapy.

Authors:  Mario P Colombo; Giorgio Trinchieri
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells.

Authors:  K Tasaki; Y Yoshida; T Maeda; M Miyauchi; K Kawamura; K Takenaga; H Yamamoto; T Kouzu; T Asano; T Ochiai; S Sakiyama; M Tagawa
Journal:  Cancer Gene Ther       Date:  2000-02       Impact factor: 5.987

6.  Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix.

Authors:  T D de Gruijl; H J Bontkes; A J van den Muysenberg; J W van Oostveen; M J Stukart; R H Verheijen; N van der Vange; P J Snijders; C J Meijer; J M Walboomers; R J Scheper
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

7.  Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

Authors:  F Cavallo; P Signorelli; M Giovarelli; P Musiani; A Modesti; M J Brunda; M P Colombo; G Forni
Journal:  J Natl Cancer Inst       Date:  1997-07-16       Impact factor: 13.506

8.  Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.

Authors:  Y Nasu; C H Bangma; G W Hull; H M Lee; J Hu; J Wang; M A McCurdy; S Shimura; G Yang; T L Timme; T C Thompson
Journal:  Gene Ther       Date:  1999-03       Impact factor: 5.250

Review 9.  Interleukin 12: a key modulator of immune function.

Authors:  S F Wolf; D Sieburth; J Sypek
Journal:  Stem Cells       Date:  1994-03       Impact factor: 6.277
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.